Gastrointestinal Neoplasms
Conditions
Interventions
This is a pragmatic, non-randomized clinical trial with 56 participants with gastrointestinal tract cancer selected from an oncology unit, from June 2023 to October 2024, biochemical information and a
G07.203.300.681
C04.588.274.476.411.307
Sponsors
Liga Norte Riograndense Contra o Câncer
Liga Norte Riograndense Contra o Câncer
Eligibility
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients of both sexes; minimum age of 20 years; with a confirmed diagnosis of cancer in the gastrointestinal tract and treated at the general surgery outpatient clinic
Exclusion criteria
Exclusion criteria: Hospitalization for less than 24 hours; patients on enteral and parenteral nutritional therapy; patients admitted to intensive care units; palliative care; pregnant women and/or individuals with infectious diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that with immunomodulatory supplementation, patients with suspected, moderate or severe malnutrition classification will present less weight loss, anthropometric measurements of arm and calf circumference. Data collected pre-surgery and post-surgery taking into account the average time of 22 days between surgery and the first post-surgery consultation | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactLaíse Mayara Oliveira
Liga Norte Riograndense Contra o Câncer
Outcome results
None listed